Blueprint Medicines Corp (NASDAQ: BPMC) stock enjoyed a major increase of 18.2% on 1/13/25. The shares closed at $103.36. Moreover, this advance was accompanied by exceptionally high trading volume at 318% of normal. The stock has been weak relative to the market over the last nine months but has risen 18.5% during the last week.
Current PriceTarget Research Rating
Blueprint Medicines has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Blueprint Medicines has a very low Power Rating of 9 and a very low Appreciation Score of 1, with the Lowest Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment